Yellow Fever Vaccine-associated Viscerotropic Disease.
- Author:
Eun Sung CHOI
1
;
Kwi Hyun BAE
;
Young Eui JEONG
;
Young Ran JU
;
Hyun Ah KIM
;
Seong Yeol RYU
Author Information
1. Department of Infectious Disease, Keimyung University School of Medicine, Daegue, Korea. 121rsy@dsmc.or.kr
- Publication Type:Case Report
- Keywords:
Yellow fever;
Hepatitis;
Vaccination
- MeSH:
Culicidae;
Enzyme-Linked Immunosorbent Assay;
Fever;
Flavivirus;
Hemorrhage;
Hepatitis;
Hospitalization;
Humans;
Immunoglobulin M;
Male;
Nausea;
Renal Insufficiency;
Shock;
Vaccination;
Yellow Fever;
Yellow Fever Vaccine;
Yellow fever virus;
Young Adult
- From:Korean Journal of Medicine
2011;80(Suppl 2):S301-S304
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
This report describes a case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) that occurred after vaccination in a 23-year-old male. Seven days after vaccination, our patient presented with fever, myalgia, and nausea. The IgM enzyme-linked immunosorbent assay (ELISA) for yellow fever virus was positive. After a 24 day hospitalization, he recovered and was discharged. Yellow fever is a viral hemorrhagic febrile illness caused by a flavivirus and transmitted by mosquitoes. The clinical presentation ranges from a mild febrile illness to a serious infection, leading to hepatic and renal failure, myocardial injury, hemorrhage, and shock, with a case fatality rate of 20-30%. Because yellow fever is a potentially fatal disease, vaccination is encouraged for people traveling to high-risk areas. Although considered a safe vaccine, severe adverse reactions have been reported. In 2001, rare, but severe, acute viscerotropic disease following vaccination was first described. We report the case of a 23-year-old male with fever and hepatitis following vaccination with 17D yellow fever vaccine.
